Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: End Stage Renal Disease
Interventions: Theranova 400 dialyzer, Elisio-17H dialyzer; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Corona, California • Riverside, California • Bloomfield, Connecticut + 15 more

Conditions: Cognitive Disorders
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Breast Cancer, Lymphedema, Physical Therapy, Shoulder
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Magnetic Resonance Imaging
Interventions: Gadopentetate dimeglumine (Magnevist, BAY86-6661); Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Parkinson Disease
Interventions: CVL-751; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Atlanta, Georgia

Conditions: Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions: Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 48
States / cities: Saraland, Alabama • Fresno, California • Harbor City, California + 41 more

Conditions: Multiple Chronic Conditions, Dementia
Interventions: Patient Priorities Care (PPC) Approach, Adapted PPC; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Surgery
Interventions: Educational Module, Salpingectomy; Behavioral · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Baltimore, Maryland • Boston, Massachusetts • Basking Ridge, New Jersey + 7 more

Conditions: Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Pediatric Growth Hormone Deficiency
Interventions: Experimental: VRS-317; Drug
Lead sponsor: Versartis Inc.; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 23
States / cities: Clovis, California • Los Angeles, California • San Diego, California + 20 more

Conditions: Bacterial Infections, Infection
Interventions: BC-3781, Vancomycin; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 6 more

Conditions: Cryptogenic Stroke
Interventions: Not listed
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Alzheimer Disease
Interventions: 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos; Drug
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infertility
Interventions: Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Pasadena, California • San Diego, California • Littleton, Colorado + 4 more

Conditions: Peri-Implantitis
Interventions: 2.5 mg Chlorhexidine gluconate chip; Drug
Lead sponsor: Dexcel Pharma Technologies Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Alzheimer Disease
Interventions: PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Sun City, Arizona • Fresno, California • San Diego, California + 9 more

Conditions: Dry Eye
Interventions: DE-110 ophthalmic suspension high dose, DE-110 ophthalmic suspension low dose, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Inglewood, California • Newport Beach, California • Petaluma, California + 11 more

Conditions: Malignant Melanoma
Interventions: RO5185426; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 8 more

Conditions: Metastatic Prostate Cancer
Interventions: lutetium (177Lu) rhPSMA 10.1 and Pluvicto®; Drug
Lead sponsor: Blue Earth Therapeutics Ltd; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions: Extension for Community Healthcare Outcomes; Other
Lead sponsor: Family Health Centers of San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Jeffrey A. Feinstein; Other
Eligibility: Up to 18 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Alzheimer Disease, Down Syndrome
Interventions: ION269; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 35 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Tampa, Florida • Sandy Springs, Georgia • Brighton, Massachusetts + 5 more

Search by objective public record fields.

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer

Contrast-enhanced MRI in Children 2 Months to <2 Years

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Patient Priorities Care for Hispanics With Dementia

A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

Versartis Trial in Children to Assess Long-Acting Growth Hormone

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

MENOPUR® Versus FOLLISTIM®

The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

The RESET System Pivotal Clinical Trial (Protocol Revision K)

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)